the anxiolytic triazolobenzodiazepine alprazolam was administered to six male patients , aged 26 to 46 years , with panic disorder or agoraphobia ( with panic attacks ) to assess clinical effects and steady-state pharmacokinetics following multiple dosing at three levels : 3.0 mg/d , 6.0 mg/d , and 9.0 mg/d .
C0002333
alprazolam
C0030319
panic disorder